Research & Development Agrmnt

Proteome Sciences PLC 3 April 2001 PRESS RELEASE 3 April 2001 PROTEOME SCIENCES ASSOCIATE, INTRONN, ANNOUNCES HPV AND CERVICAL CANCER R& D AGREEMENT WITH NATIONAL CANCER INSTITUTE USING INTRONN'S SMARTTM TECHNOLOGY. Proteome Sciences plc, the AIM listed proteomics and gene expression research company, is pleased to announce that its US associate, Intronn LLC, has signed a cooperative research and development agreement (CRADA) with the laboratory of Dr. Carl Baker of the National Cancer Institute (NCI) within the National Institutes of Health in the USA. The agreement will involve Intronn and Dr. Baker combining their expertise and experience to develop an RNA based treatment for human papillomavirus infection (HPV) and cervical cancers induced by HPV infection. Dr. Baker's laboratory and Intronn will use Intronn's patented spliceosome mediated mRNA trans-splicing (SMaRTTM) technology to create highly specific treatments for human HPV infections and HPV-induced cervical cancers. Most cervical cancers are correlated with HPV infection. Commenting on this news Christopher Pearce, Chief Executive of Proteome Sciences said:- 'Having the NCI, one of the world's most advanced cancer research centres, choose to work in collaboration with Intronn using its SMaRT platform is a recognition of the tremendous potential that this trans-splicing technology has as a therapeutic treatment for oncology based conditions'. Intronn has developed its proprietary SMaRTTM technology which has specific applications in genomics, gene knockdown and exon swapping that can be used in the human therapeutics and agriculture markets. ENDS For additional information contact: Proteome Sciences Christopher Pearce, Chief Executive Tel: 01932 865065 Gerard J. McGarrity, Ph.D. CEO, Intronn LLC Tel: 001 919 831 2239 Public Relations Ikon Associates Adrian Shaw Tel: 01483 271291 Mobile: 0797 9900733 E-mail: adrian@ikon-associates.com